Oncology Nursing Drug Guide Downloads & RevenueOncology Nursing Drug Guide · App Store
Not in any tracked top chart right now.
Updated 5 Nov 2026 · rankings refresh through the day
DeveloperAtmosphere Apps, Inc.
CategoryMedical
PriceFree
Released
Rating★ 5.0 (1)
Version2.0.2.104
Age rating17+
First seen by us
1 Oct 2026
1 Oct 2026Installs (est.)1k+ worldwide
Oncology Nursing Drug Guide update history & changes
Last change · 4 events since 31 May 2018Full timeline ↓Full timeline · 3 events in the last 12 months
- 📈Oncology Nursing Drug Guide dropped out of every chart we trackLast seen 7 Oct
- 🆕Oncology Nursing Drug Guide first spotted by AppInsider#25 in Top Grossing · Medical · South Korea
- 🆕Oncology Nursing Drug Guide released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
5.0 ★
1 ratings
Measured
Oncology Nursing Drug Guide on the App Store
App details
App ID
1350544647
Publisher
Atmosphere Apps, Inc.
On the store since
May 2018
8 years on the store
Minimum OS
iOS 11.0+
iPhone 5s and later
Devices
iPhone · iPad
Universal purchase
Content rating
17+
Languages
1
EN
Size
57 MB
Also listed in
Education
Oncology Nursing Drug Guide downloads
Worldwide, per day, and installs to date. The band is open; the exact number is free with an account.
How this is calculated
Apple publishes no download counts. App Store downloads come from chart positions and daily rating growth per country, calibrated on Google Play install counts; lifetime installs from ratings worldwide × installs per rating. Confidence is the chance the real number is within half to double ours.
Active users
All platforms, worldwide. Free with an account.
Stickiness (DAU / MAU)
how many monthly users open it on a given day
How this is calculated
Monthly users come from lifetime installs across every store, fitted on monthly active user figures companies publish; daily users = monthly × the typical daily/monthly ratio for the category. Confidence is the chance the real number is within half to double ours.
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Not charting right now. | ||
Ratings
App Store, worldwide.
Rating
5.0 ★
1 ratings
Measured
Ratings
1
Measured
Review momentum
ⓘ How we measure thisNew ratings a week
under 1
4-week average
Lifetime rating
5.0★
recent stars not readable yet: new ratings are a tiny share of the total
Review momentum
20/100
faster than 0% of Medical apps
Review momentum (0-100) blends how fast the app collects ratings compared with other apps in its category (60%), whether that pace is speeding up (25%) and what recent raters give it (15%; recent stars well below lifetime pull it down). Ratings counts are read daily. A jump usually means a launch, a feature, ads or a new review prompt.
About Oncology Nursing Drug Guide
Written especially for nurses caring for patients with cancer, the Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include:
apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)
Subscriptions are $9.99 for one year. Your subscription will auto-renew annually at the end of each year-long term, unless cancelled. Payment will be charged to your iTunes Account at confirmation of purchase. The subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Your account will be charged $9.99 for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed and auto-renewal may be turned off by going to your Account Settings after purchase. No cancellation of the current subscription is allowed during active subscription period. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication. Please see the links to our privacy policy and terms of service below.
Privacy Policy - http://www.jblearning.com/privacy/
Terms of Use - http://www.jblearning.com/use/
Print Book - http://www.jblearning.com/catalog/9781284054613/
Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include:
apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)
Subscriptions are $9.99 for one year. Your subscription will auto-renew annually at the end of each year-long term, unless cancelled. Payment will be charged to your iTunes Account at confirmation of purchase. The subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Your account will be charged $9.99 for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed and auto-renewal may be turned off by going to your Account Settings after purchase. No cancellation of the current subscription is allowed during active subscription period. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication. Please see the links to our privacy policy and terms of service below.
Privacy Policy - http://www.jblearning.com/privacy/
Terms of Use - http://www.jblearning.com/use/
Print Book - http://www.jblearning.com/catalog/9781284054613/
Latest updates
2.0.2.104
Updated data
Framework improvements
